Stuart Lessin, a board-certified dermatologist who serves as KGL's medical director. The Phase IIa clinical study will be conducted by KGL Skin Center, a Philadelphia-based independent clinical research facility recognized as a leader in clinical testing of cosmetics, personal care products, over-the-counter and prescription drugs, and devices for the skin. This is the first clinical study in the clinical development program for BPX-01. This clinical study will assess effectiveness in reducing the number of acne-causing bacteria in study patients at four weeks and evaluate the drug's safety and tolerability. On March 3, 2016, BioPharmX announced that it will immediately commence a Phase IIa clinical study under its U.S. Following the conclusion of the meeting, the company believes that it has sufficient guidance from the FDA for advancing toward an IND application for phase II clinical trials. In March 2015, BioPharmX completed its planned pre-IND (Investigational New Drug) meeting with the US FDA which was focused on the company's proposed strategy for advancing BPX01and plans for conducting safety and toxicology studies, along with human clinical trials. acnes bacteria without the systemic side effects of orally-administered antibiotics. BPX01 utilizes a transepidermal delivery mechanism for minocycline and other APIs that has the potential to kill p. BioPharmX ( BPMX) is developing BPX01, a non-lipophilic, topical antibiotic for the treatment of acne.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |